The growth hormone fragment that burns fat without touching your blood sugar.
AOD-9604 is a 15-amino-acid snippet of human growth hormone — specifically the lipolytic section. It activates β3 adrenergic receptors in your fat tissue, triggering the breakdown of stored triglycerides while simultaneously blocking new fat formation. The key difference from full growth hormone: it doesn't raise IGF-1, doesn't affect insulin sensitivity, and doesn't spike blood glucose. The FDA granted it GRAS status after Phase II clinical trials showed significant fat loss versus placebo with zero metabolic side effects. Fat-specific. Blood-sugar neutral. No receptor interference.
AOD-9604
Anti-Obesity Drug 9604 (hGH fragment 177–191)
AOD-9604 is a stabilised peptide fragment of human growth hormone (amino acids 177–191) specifically isolated for its lipolytic and anti-lipogenic effects. Unlike full hGH, it does not raise IGF-1 or affect blood glucose, making it a targeted fat-loss tool with a clean safety profile.
Technical details
- CAS number
- 221231-10-3
- Molecular formula
- C78H123N23O23S2
MECHANISM OF ACTION
AOD-9604 selectively activates β3 adrenergic receptors in adipose tissue, triggering lipolysis — the breakdown of stored triglycerides into free fatty acids. Simultaneously it inhibits lipogenesis (new fat formation). Unlike full GH, it does not stimulate the liver to produce IGF-1 and has no diabetogenic effect. In obese Zucker rat models it produced dose-dependent fat reduction without affecting lean mass, insulin sensitivity, or bone density.
RESEARCH HIGHLIGHTS
Dose-dependent reduction in body fat in obese Zucker rats without affecting lean mass or insulin sensitivity
β3 adrenergic receptor-dependent lipolytic activity confirmed; does not stimulate IGF-1 or affect glucose metabolism
Phase IIb clinical trial (USA) shows significant fat loss vs placebo with no adverse metabolic effects
GRAS status granted by FDA following phase I/II human trials — classified as generally recognized as safe
RESEARCH PROTOCOLS
For laboratory use only. Not medical advice.
Administer 30 min before morning cardio or first meal. Fasted state enhances lipolytic effect.
Most-studied dose range. Stack with CJC-1295 + Ipamorelin for lean recomposition. Monitor body composition at 4-week intervals.
Upper range of human trial dosing. No additional benefit demonstrated above 500mcg. Consider splitting into two 250mcg doses for stubborn areas.
PAIRS WELL WITH
ORDER
SAFETY & CONTRAINDICATIONS
- Active malignancy (growth factor sensitivity — use with caution)
- Pregnancy or breastfeeding
- Known hypersensitivity to GH peptide fragments
- Type 1 diabetes (unclear interaction with beta-cell function)
Well-tolerated in clinical trials. Reported effects: transient injection-site redness, mild facial flushing in first 1–2 weeks, water retention at higher doses. No insulin resistance, no IGF-1 elevation, no hypoglycaemia observed in any trial.
For research and laboratory use only. Not intended for human consumption. Not for diagnostic or therapeutic purposes.